Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Bluejay Diagnostics (NASDAQ:BJDX) agreed to a private placement of 3,655,917 common shares (or pre-funded warrants) plus series G and H warrants, raising expected gross proceeds of $8.5 million, with up to $15.1 million additional if all warrants are exercised for cash.
According to Bluejay, net proceeds should extend its cash runway into Q1 2027, beyond the expected FDA submission, and potentially beyond FDA approval and the first full year of commercialization if all warrants are exercised, funding FDA-related activities, R&D, and working capital.
AI-generated analysis. Not financial advice.
Positive
- Private placement expected to raise $8.5 million in gross proceeds
- Additional potential $15.1 million from full cash exercise of series G and H warrants
- Cash runway anticipated to extend into Q1 2027 beyond expected FDA submission
- Proceeds earmarked for FDA approval efforts, clinical studies, R&D, and working capital
Negative
- Issuance of 3,655,917 shares plus equal number of warrant shares implies dilution
- No assurance that series G and H warrants will be exercised or provide $15.1 million
- Offering conducted as a private placement, with resale dependent on future registration statement effectiveness
Key Figures
Market Reality Check
Peers on Argus
BJDX was up 1.4% pre-announcement while peers were mixed: AEMD down 10.37%, HSCS up 8.37%. With peers moving in both directions, this points to stock-specific dynamics rather than a sector-wide move.
Previous Private placement Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 10 | Private placement closing | Neutral | -10.7% | Closed $4.5M private placement with Series F warrants to fund FDA work. |
| Oct 09 | Private placement announced | Neutral | +75.4% | Announced $4.5M at-the-market private placement with Series F warrants. |
Historically, Bluejay’s private placement announcements have triggered large but mixed price reactions, with both sharp gains and notable selloffs around financing news.
Over the past six months, Bluejay has repeatedly highlighted its need for additional capital to fund Symphony IL‑6 development and FDA efforts, including a $4.5M private placement in October 2025. Subsequent updates emphasized cash levels around $3.7M, going-concern risk, and the expectation of raising at least $20M by end of 2027. The current at‑the‑market private placement continues this pattern of using equity-linked financings with warrants to support regulatory and commercialization plans.
Historical Comparison
Past private placement announcements for BJDX produced average moves of about 32.37%, showing that financing news has historically been a major trading catalyst for the stock.
Private placement financings have been used repeatedly to fund FDA approval efforts, clinical studies, and working capital, following a similar structure of common stock plus long-dated warrants.
Regulatory & Risk Context
An effective resale registration filed in October 2025 covers up to 6,930,000 shares held by selling stockholders, mainly from prior PIPE and warrant issuances. Bluejay does not sell shares under this registration and only receives proceeds if outstanding warrants are exercised for cash, subject to beneficial ownership limits of 4.99% or 9.99% on certain warrants.
Market Pulse Summary
This announcement details an at-the-market private placement raising $8.5 million upfront, with up to $15.1 million in additional gross proceeds if warrants are fully exercised. Management expects this to extend the cash runway into the first quarter of 2027, supporting FDA-related studies and working capital. Historically, Bluejay has relied on similar private placements and warrants to fund Symphony IL‑6 development. Investors may watch execution on FDA milestones, use of proceeds, and any further equity-linked financings.
Key Terms
private placement financial
pre-funded warrant financial
warrants financial
exercise price financial
registration statement regulatory
AI-generated analysis. Not financial advice.
Net proceeds anticipated to extend cash runway into first quarter of 2027, beyond expected FDA submission; if warrants are exercised in full for cash, it is anticipated that the cash runway would extend well beyond FDA approval and first full year of commercialization
ACTON, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on near-patient testing for critical care, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,655,917 shares of common stock (or pre-funded warrant in lieu thereof), series G warrants to purchase up to 3,655,917 shares of common stock and short-term series H warrants to purchase up to 3,655,917 shares of common stock at a purchase price of
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The gross proceeds from the offering are expected to be
The securities described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the securities issued in the private placement and shares of common stock underlying the warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement with investors, the Company has agreed to file a resale registration statement covering the securities described above.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Bluejay Diagnostics:
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ‘sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.
Forward-looking Statements
This press release contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Litigation Reform Act. Forward-looking statements in this press release include, without limitation, statements related to the completion of the offering, the satisfaction of customary closing conditions related to the offering, the intended use of proceeds therefrom and the potential exercise of the series warrants prior to their expiration and potential proceeds therefrom. Forward-looking statements may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “suggest,” “will,” and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including market and other conditions and those discussed under Part I, Item 1A, “Risk Factors” in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in Part II, Item 1A, “Risk Factors” in its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026, as such factors may be updated from time to time in other filings with the SEC and accessible on the SEC’s website at www.sec.gov. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may not occur or may be materially different from any future results or performance suggested by the forward-looking statements in this release. This press release speaks as of the date indicated above. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the Company’s expectations of results or any future change in events, except as required by law.
Investor Contact:
Investor Relations
Bluejay Diagnostics, Inc.
ir@bluejaydx.com
Website: www.bluejaydx.com
